NCI Scientists Find Specific Mutation in the Breast Cancer Gene

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 11
Volume 4
Issue 11

BETHESDA, Md-Scientists from the National Cancer Institute have found a specific mutation, 185delAG, in the breast cancer 1 gene (BRCA1) in almost 1% of DNA samples from a study group of Eastern European (Ashkenazi) Jews. This is the first time that scientists have been able to show that the gene mutation is present at measurable levels not only in high-risk families but also in a specific group of the general population.

BETHESDA, Md-Scientists from the National Cancer Institute havefound a specific mutation, 185delAG, in the breast cancer 1 gene(BRCA1) in almost 1% of DNA samples from a study group of EasternEuropean (Ashkenazi) Jews. This is the first time that scientistshave been able to show that the gene mutation is present at measurablelevels not only in high-risk families but also in a specific groupof the general population.

At a press conference, Donna Shalala, secretary of the US Departmentof Health and Human Services, said that "this exciting findingshould allow us to move rapidly toward our goal of identifyinghigh-risk women and helping them to prevent breast cancer beforeit strikes."

The study, an international collaboration between the NationalCenter for Human Genome Research (NCHGR), the NCI, the SarettInstitute (Jerusalem), and the University of California, San Diego,involved 858 unrelated Ashkenazi Jews from the United States andIsrael whose family or personal cancer histories were not known.

Eight (1%) of the individuals tested were found to have the 185delAGmutation. This rate of alteration in the BRCA1 gene is three timeshigher than all BRCA1 alterations combined in the general population.Scientists did not find the alteration in 815 other samples fromindividuals not selected for ethnic origins.

Dr. Jeffery Struewing, lead author of the report (Nature Genetics,October, 1995), cautioned that the results were too preliminaryto recommend immediate BRCA1 testing for the nation's 5.5 millionAshkenazi Jews. However, NIH has announced plans to launch a seriesof clinical studies to evaluate cancer risk in Ashkenazi Jewsbearing the mutation.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content